Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) announced its earnings results on Tuesday. The biotechnology company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03, Zacks reports. During the same period in the prior year, the business earned ($0.13) earnings per share.
Anavex Life Sciences Stock Down 4.5%
Shares of NASDAQ AVXL traded down $0.39 during trading hours on Tuesday, hitting $8.17. 255,040 shares of the stock were exchanged, compared to its average volume of 1,219,311. Anavex Life Sciences has a 12 month low of $3.51 and a 12 month high of $14.44. The company has a market cap of $697.06 million, a PE ratio of -14.85 and a beta of 0.82. The firm has a fifty day moving average price of $8.93 and a 200-day moving average price of $9.06.
Wall Street Analyst Weigh In
AVXL has been the topic of a number of research reports. HC Wainwright reaffirmed a "buy" rating and set a $42.00 target price on shares of Anavex Life Sciences in a research note on Monday, April 7th. D. Boral Capital reissued a "buy" rating and set a $46.00 price target on shares of Anavex Life Sciences in a research report on Monday, April 7th.
Check Out Our Latest Stock Report on AVXL
Anavex Life Sciences Company Profile
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
